On which evidence can we rely when prescribing off-label methotrexate in dermatological practice? – a systematic review with GRADE approach

References

• Franca K, Litewka S. Controversies in off-label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies. Int J Dermatol. 2019;58(7):788–794.
   PubMed Web of Science ®Google Scholar
• Picard D, Carvalho P, Bonnavia C, et al. Assessment off-label prescribing in dermatology. Ann Dermatol Venereol. 2003;130(5):507–510.
   PubMed Web of Science ®Google Scholar
• Sugarman JH, Fleischer AB Jr., Feldman SR. Off-label prescribing in the treatment of dermatologic disease. J Am Acad Dermatol. 2002;47(2):217–223.
   PubMed Web of Science ®Google Scholar
• Aronson JK, Ferner RE. Unlicensed and off-label uses of medicines: definitions and clarification of terminology. Br J Clin Pharmacol. 2017;83(12):2615–2625.
   PubMed Web of Science ®Google Scholar
• Schram ME, Borgonjen RJ, Bik CM, et al. Off-label use of azathioprine in dermatology: a systematic review. Arch Dermatol. 2011;147(4):474–488.
   PubMedGoogle Scholar
• Ghaoui N, Hanna E, Abbas O, et al. Update on the use of dapsone in dermatology. Int J Dermatol. 2020;59(7):787–795.
   PubMed Web of Science ®Google Scholar
• Vermeulen FM, Gerbens LAA, Schmitt J, et al. The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate-to-severe atopic eczema. Br J Dermatol. 2020;183(6):1073–1082.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Kodama S. Atopic dermatitis guidelines: diagnosis, systemic therapy, and adjunctive care. Clin Dermatol. 2018;36(5):648–652.
   PubMed Web of Science ®Google Scholar
• Weda M, Hoebert J, Vervloet M, et al. Study on off-label use of medicinal products in the European Union. Directorate-General for Health and Food Safety (European Commission); 2017. Available from: https://ec.europa.eu/health/sites/default/files/files/documents/2017_02_28_final_study_report_on_off-label_use_.pdf.
   Google Scholar
• Geneesmiddelenwet artikel 68; 2007 [cited 2021 Jun 3]. Available from: https://wetten.overheid.nl/jci1.3:c.:BWBR0021505&hoofdstuk=6&artikel=68&z=2020-04-01&g=2020-04-01
   Google Scholar
• Bieber T, Straeter B. Off-label prescriptions for atopic dermatitis in Europe. Allergy. 2015;70(1):6–11.
   PubMed Web of Science ®Google Scholar
• Shen S, O'Brien T, Yap LM, et al. The use of methotrexate in dermatology: a review. Australas J Dermatol. 2012;53(1):1–18.
   PubMed Web of Science ®Google Scholar
• Diani M, Grasso V, Altomare G. Methotrexate: practical use in dermatology. G Ital Dermatol Venereol. 2016;151(5):535–543.
   PubMed Web of Science ®Google Scholar
• Warren RB, Weatherhead SC, Smith CH, et al. British association of dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.[erratum appears in Br J Dermatol. 2017 jun;176(6):1678; PMID: 28581246]. Br J Dermatol. 2016;175(1):23–44.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, GRADE Working Group, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–926.
   PubMed Web of Science ®Google Scholar
• NHS. PROSPERO – International prospective register of systematic reviews; 2017 [cited 2021 Apr 19]. Available from: https://www.crd.york.ac.uk/PROSPERO/
   Google Scholar
• Criteria for applying or using GRADE; 2016 [cited 2021 Jun 3]. Available from: https://www.gradeworkinggroup.org/docs/Criteria_for_using_GRADE_2016-04-05.pdf
   Google Scholar
• Guyatt G, Oxman A, Akl E, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–394.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.
   PubMed Web of Science ®Google Scholar
• Downham TF, Chapel TA. Bullous pemphigoid: therapy in patients with and without diabetes mellitus. Arch Dermatol. 1978;114(11):1639–1642.
   PubMedGoogle Scholar
• Ho V, Dutz J. Methotrexate–The value of case series for older drugs. J Cutan Med Surg. 2018;22(5):537.
   PubMed Web of Science ®Google Scholar
• Rivitti EA, Camargo ME, Castro RM, et al. Use of methotrexate to treat pemphigus foliaceus. Int J Dermatol. 1973;12(2):119–122.
   PubMedGoogle Scholar
• Egan CA, Rallis TM, Meadows KP, et al. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx. J Am Acad Dermatol. 1999;40(4):612–614.
   PubMed Web of Science ®Google Scholar
• Peck SM, Osserman KE, Samuels AJ, et al. Studies in bullous diseases. Treatment of pemphigus vulgaris with immunosuppressives (steroids and methotrexate) and leucovorin calcium. Arch Dermatol. 1971;103(2):141–147.
   PubMedGoogle Scholar
• Kasteler JS, Callen JP. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis. J Am Acad Dermatol. 1997;36(1):67–71.
   PubMed Web of Science ®Google Scholar
• Lajevardi V, Ghodsi SZ, Hallaji Z, et al. Treatment of erosive oral lichen planus with methotrexate. J Dtsch Dermatol Ges. 2016;14(3):286–293.
   PubMed Web of Science ®Google Scholar
• Hornung T, Ko A, Tuting T, et al. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol. 2012;37(2):139–142.
   PubMed Web of Science ®Google Scholar
• Goujon C, Viguier M, Staumont-Salle D, et al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial. J Allergy Clin Immunol Pract. 2017;2(6):562–569.e3.
   Google Scholar
• Torok KS, Arkachaisri T. Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol. 2012;39(2):286–294.
   PubMed Web of Science ®Google Scholar
• Shah N, Alhusayen R, Walsh S, et al. Methotrexate in the treatment of moderate to severe atopic dermatitis: a retrospective study. J Cutan Med Surg. 2018;22(5):484–487.
   PubMed Web of Science ®Google Scholar
• Malekzad F, Saeedi M, Ayatollahi A. Low dose methotrexate for the treatment of generalized lichen planus. Iran J Dermatol. 2012;14(58):131–135.
   Google Scholar
• Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Rheumatol Int. 1998;18(2):59–62.
   PubMed Web of Science ®Google Scholar
• Baum S, Greenberger S, Samuelov L, et al. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol. 2012;22(1):83–87.
   PubMed Web of Science ®Google Scholar
• Christen-Zaech S, Hakim MD, Afsar FS, et al. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59(3):385–396.
   PubMed Web of Science ®Google Scholar
• Kwatra SG, Jorizzo JL. Bullous pemphigoid: a case series with emphasis on long-term remission off therapy. J Dermatolog Treat. 2013;24(5):327–331.
   PubMed Web of Science ®Google Scholar
• AlGhamdi K, Khurrum H. Methotrexate for the treatment of generalized vitiligo. Saudi Pharm J. 2013;21(4):423–424.
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, De D. Methotrexate for treatment of lichen planus: old drug, new indication. J Eur Acad Dermatol Venereol. 2013;27(3):e410–e413.
   PubMed Web of Science ®Google Scholar
• Ilyas S, Inayat S, Khurshid K, et al. Efficacy and safety of methotrexate in lichen planus. J Pak Assoc Dermatol. 2016;26(1):41–47.
   Google Scholar
• Tran KD, Wolverton JE, Soter NA. Methotrexate in the treatment of pemphigus vulgaris: experience in 23 patients. Br J Dermatol. 2013;169(4):916–921.
   PubMed Web of Science ®Google Scholar
• Koch SB, Cerci FB, Jorizzo JL, et al. Linear morphea: a case series with long-term follow-up of young, methotrexate-treated patients. J Dermatolog Treat. 2013;24(6):435–438.
   PubMed Web of Science ®Google Scholar
• Shahidi-Dadras M, Abdollahimajd F, Jahangard R, et al. Magnetic resonance imaging evaluation in patients with linear morphea treated with methotrexate and high-dose corticosteroid. Dermatol Res Pract. 2018;2018:8391218.
   PubMed Web of Science ®Google Scholar
• Roekevisch E, Schram ME, Leeflang MMG, et al. Methotrexate versus azathioprine in patients with atopic dermatitis: 2-year follow-up data. J Allergy Clin Immunol. 2018;141(2):825–827.e10.
   PubMed Web of Science ®Google Scholar
• Schram ME, Roekevisch E, Leeflang MM, et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128(2):353–359.
   PubMed Web of Science ®Google Scholar
• Mertens JS, Zweers MC, Kievit W, et al. High-dose intravenous pulse methotrexate in patients with eosinophilic fasciitis. JAMA Dermatol. 2016;152(11):1262–1265.
   PubMed Web of Science ®Google Scholar
• Roberts H, Orchard D. Methotrexate is a safe and effective treatment for paediatric discoid (nummular) eczema: a case series of 25 children. Australas J Dermatol. 2010;51(2):128–130.
   PubMed Web of Science ®Google Scholar
• Singh H, Kumaran MS, Bains A, et al. A randomized comparative study of oral corticosteroid minipulse and low-dose oral methotrexate in the treatment of unstable vitiligo. Dermatology. 2015;231(3):286–290.
   PubMed Web of Science ®Google Scholar
• Bakker CV, Terra JB, Pas HH, et al. Bullous pemphigoid as pruritus in the elderly: a common presentation. JAMA Dermatol. 2013;149(8):950–953.
   PubMed Web of Science ®Google Scholar
• Tetart F, Joly P. Low doses of methotrexate for the treatment of chronic eczema in the elderly. J Eur Acad Dermatol Venereol. 2011;25(11):1364–1365.
   PubMed Web of Science ®Google Scholar
• Platsidaki E, Tzanetakou V, Kouris A, et al. Methotrexate: an effective monotherapy for refractory generalized morphea. Clin Cosmet Investig Dermatol. 2017;10:165–169.
   PubMed Web of Science ®Google Scholar
• Zulian F, Martini G, Vallongo C, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998–2006.
   PubMedGoogle Scholar
• Purvis D, Lee M, Agnew K, et al. Long-term effect of methotrexate for childhood atopic dermatitis. J Paediatr Child Health. 2019;55(12):1487–1491.
   PubMed Web of Science ®Google Scholar
• Naka F, Strober BE. Methotrexate treatment of generalized granuloma annulare: a retrospective case series. J Dermatolog Treat. 2018;29(7):720–724.
   PubMed Web of Science ®Google Scholar
• Gansauge S, Breitbart A, Rinaldi N, et al. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis. 1997;56(6):382–385.
   PubMed Web of Science ®Google Scholar
• Lyakhovitsky A, Barzilai A, Heyman R, et al. Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults. J Eur Acad Dermatol Venereol. 2010;24(1):43–49.
   PubMed Web of Science ®Google Scholar
• Zulian F, Vallongo C, Patrizi A, et al. A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea). J Am Acad Dermatol. 2012;67(6):1151–1156.
   PubMed Web of Science ®Google Scholar
• Knopfel N, Noguera-Morel L, Hernandez-Martin A, et al. Methotrexate for severe nummular eczema in children: efficacy and tolerability in a retrospective study of 28 patients. Pediatr Dermatol. 2018;35(5):611–615.
   PubMed Web of Science ®Google Scholar
• Sagi L, Solomon M, Baum S, et al. Evidence for methotrexate as a useful treatment for steroid-dependent chronic urticaria. Acta Derm Venereol. 2011;91(3):303–306.
   PubMed Web of Science ®Google Scholar
• Lucas P, Bodemer C, Barbarot S, et al. Methotrexate in severe childhood alopecia areata: long-term follow-up. Acta Derm Venereol. 2016;96(1):102–103.
   PubMed Web of Science ®Google Scholar
• Droitcourt C, Milpied B, Ezzedine K, et al. Interest of high-dose pulse corticosteroid therapy combined with methotrexate for severe alopecia areata: a retrospective case series. Dermatology. 2012;224(4):369–373.
   PubMed Web of Science ®Google Scholar
• Cox D, O'Regan G, Collins S, et al. Juvenile localized scleroderma: a retrospective review of respons to systemic treatment. Iran J Med Sci. 2008;177(4):343–346.
   PubMed Web of Science ®Google Scholar
• Deo M, Yung A, Hill S, et al. Methotrexate for treatment of atopic dermatitis in children and adolescents. Int J Dermatol. 2014;53(8):1037–1041.
   PubMed Web of Science ®Google Scholar
• Heilborn JD, Stahle-Backdahl M, Albertioni F, et al. Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1999;40(5 Pt 1):741–749.
   PubMed Web of Science ®Google Scholar
• El-Khalawany MA, Hassan H, Shaaban D, et al. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. Eur J Pediatr. 2013;172(3):351–356.
   PubMed Web of Science ®Google Scholar
• Mertens JS, van den Reek JM, Kievit W, et al. Drug survival and predictors of drug survival for methotrexate treatment in a retrospective cohort of adult patients with localized scleroderma. Acta Derm Venereol. 2016;96(7):943–947.
   PubMed Web of Science ®Google Scholar
• Perez A, Woods A, Grattan CE. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol. 2010;162(1):191–194.
   PubMed Web of Science ®Google Scholar
• Fitch PG, Rettig P, Burnham JM, et al. Treatment of pediatric localized scleroderma with methotrexate. J Rheumatol. 2006;33(3):609–614.
   PubMed Web of Science ®Google Scholar
• Lim SK, Lim CA, Kwon IS, et al. Low-Dose systemic methotrexate therapy for recalcitrant alopecia areata. Ann Dermatol. 2017;29(3):263–267.
   PubMed Web of Science ®Google Scholar
• Rattanakaemakorn P, Jorizzo JL. The efficacy of methotrexate in the treatment of en coup de sabre (linear morphea subtype). J Dermatolog Treat. 2017;29:197–199.
   PubMed Web of Science ®Google Scholar
• Zoller L, Ramon M, Bergman R. Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema. Isr Med Assoc J. 2008;10(6):413–414.
   PubMed Web of Science ®Google Scholar
• Kroft EB, Creemers MC, van den Hoogen FH, et al. Effectiveness, side-effects and period of remission after treatment with methotrexate in localized scleroderma and related sclerotic skin diseases: an inception cohort study. Br J Dermatol. 2009;160(5):1075–1082.
   PubMed Web of Science ®Google Scholar
• Schanz S, Henes J, Ulmer A, et al. Response evaluation of musculoskeletal involvement in patients with deep morphea treated with methotrexate and prednisolone: a combined MRI and clinical approach. Am J Roentgenol. 2013;200(4):W376–W382.
   PubMed Web of Science ®Google Scholar
• Breuckmann F, Appelhans C, Harati A, et al. Failure of low-dose methotrexate in the treatment of scleredema diabeticorum in seven cases. Dermatology. 2005;211(3):299–301.
   PubMed Web of Science ®Google Scholar
• Chartaux E, Joly P. [Long-term follow-up of the efficacy of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia areata totalis or universalis]. Ann Dermatol Venereol. 2010;137(8–9):507–513.
   PubMed Web of Science ®Google Scholar
• Hammerschmidt M, Brenner FM. Efficacy and safety of methotrexate in alopecia areata. An Bras Dermatol. 2014;89(5):729–734.
   PubMed Web of Science ®Google Scholar
• Thi Van AT, Lan AT, Anh MH, et al. Efficacy and safety of methotrexate in combination with mini pulse doses of methylprednisolone in severe alopecia areata. The Vietnamese experience. Open Access Maced J Med Sci. 2019;7(2):200–203.
   PubMedGoogle Scholar
• Alkeraye S, Becquart C, Delaporte E, et al. Efficacy of combining pulse corticotherapy and methotrexate in alopecia areata: real-life evaluation. J Dermatol. 2017;44(12):e319–e320.
   PubMed Web of Science ®Google Scholar
• Anuset D, Perceau G, Bernard P, et al. Efficacy and safety of methotrexate combined with low- to moderate-dose corticosteroids for severe alopecia areata. Dermatology. 2016;232(2):242–248.
   PubMed Web of Science ®Google Scholar
• Chong JH, Taieb A, Morice-Picard F, et al. High-dose pulsed corticosteroid therapy combined with methotrexate for severe alopecia areata of childhood. J Eur Acad Dermatol Venereol. 2017;31(11):e476–e477.
   PubMed Web of Science ®Google Scholar
• Firooz AR, Fouladi DF. Methotrexate plus prednisolone in severe alopecia areata. Am J Drug Discov Dev. 2013;3(3):188–193.
   Google Scholar
• Joly P. The use of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia totalis or universalis. J Am Acad Dermatol. 2006;55(4):632–636.
   PubMed Web of Science ®Google Scholar
• Landis ET, Pichardo-Geisinger RO. Methotrexate for the treatment of pediatric alopecia areata. J Dermatolog Treat. 2017;29:145–148.
   PubMed Web of Science ®Google Scholar
• Royer M, Bodemer C, Vabres P, et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata. Br J Dermatol. 2011;165(2):407–410.
   PubMed Web of Science ®Google Scholar
• Vano-Galvan S, Fernandez-Crehuet P, Grimalt R, et al. Alopecia areata totalis and universalis: a multicenter review of 132 patients in Spain. J Eur Acad Dermatol Venereol. 2017;31(3):550–556.
   PubMed Web of Science ®Google Scholar
• Hegazy S, Tauber M, Bulai-Livideanu C, et al. Systemic treatment of severe adult atopic dermatitis in clinical practice: analysis of prescribing pattern in a cohort of 241 patients. J Eur Acad Dermatol Venereol. 2017;31(9):e423–e4.
   PubMed Web of Science ®Google Scholar
• Dvorakova V, O'Regan GM, Irvine AD. Methotrexate for severe childhood atopic dermatitis: clinical experience in a tertiary center. Pediatr Dermatol. 2017;34(5):528–534.
   PubMed Web of Science ®Google Scholar
• Anderson K, Putterman E, Rogers RS, et al. Treatment of severe pediatric atopic dermatitis with methotrexate: a retrospective review. Pediatr Dermatol. 2019;36(3):298–302.
   PubMed Web of Science ®Google Scholar
• Gerbens LAA, Hamann SAS, Brouwer MWD, et al. Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. Br J Dermatol. 2018;178(6):1288–1296.
   PubMed Web of Science ®Google Scholar
• Weatherhead SC, Wahie S, Reynolds NJ, et al. An open-label, dose-ranging study of methotrexate for moderate-to-severe adult atopic eczema. Br J Dermatol. 2007;156(2):346–351.
   PubMed Web of Science ®Google Scholar
• Taieb Y, Baum S, Ben Amitai D, et al. The use of methotrexate for treating childhood atopic dermatitis: a multicenter retrospective study. J Dermatolog Treat. 2019;30(3):240–244.
   PubMed Web of Science ®Google Scholar
• Rahman SI, Siegfried E, Flanagan KH, et al. The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children. J Am Acad Dermatol. 2014;70(2):252–256.
   PubMed Web of Science ®Google Scholar
• Syed AR, Aman S, Nadeem M, et al. The efficacy and safety of oral methotrexate in chronic eczema. J Pak Assoc Dermatol. 2009;19(4):220–224.
   Google Scholar
• Mittal A, Khare A, Gupta L, et al. Use of methotrexate in recalcitrant eczema. Indian J Dermatol. 2011;56(2):232.
   PubMedGoogle Scholar
• Goujon C, Berard F, Dahel K, et al. Methotrexate for the treatment of adult atopic dermatitis. Eur J Dermatol. 2006;16(2):155–158.
   PubMed Web of Science ®Google Scholar
• Vedie AL, Ezzedine K, Amazan E, et al. Long-term use of systemic treatments for moderate-to-severe atopic dermatitis in adults: a monocentric retrospective study. Acta Derm Venereol. 2016;96(6):802–806.
   PubMed Web of Science ®Google Scholar
• Delcasso B, Goujon C, Hacard F, et al. Tolerance of methotrexate in a daily practice cohort of adults with atopic dermatitis. Eur J Dermatol. 2018;28(2):266–267.
   PubMed Web of Science ®Google Scholar
• Baum S, Porat S, Lyakhovitsky A, et al. Adult atopic dermatitis in hospitalized patients: comparison between those with childhood-onset and late-onset disease. Dermatology. 2019;235(5):365–371.
   PubMed Web of Science ®Google Scholar
• Politiek K, van der Schaft J, Coenraads PJ, et al. Drug survival for methotrexate in a daily practice cohort of adult patients with severe atopic dermatitis. Br J Dermatol. 2016;174(1):201–203.
   PubMed Web of Science ®Google Scholar
• Du-Thanh A, Merlet S, Maillard H, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol. 2011;165(6):1337–1343.
   PubMed Web of Science ®Google Scholar
• Bara C, Maillard H, Briand N, et al. Methotrexate for bullous pemphigoid: preliminary study. Arch Dermatol. 2003;139(11):1506–1507.
   PubMedGoogle Scholar
• Dereure O, Bessis D, Guillot B, et al. Treatment of bullous pemphigoid by low-dose methotrexate associated with short-term potent topical steroids: an open prospective study of 18 cases. Arch Dermatol. 2002;138(9):1255–1256.
   PubMedGoogle Scholar
• Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol. 2008;144(5):612–616.
   PubMedGoogle Scholar
• Kremer N, Zeeli T, Sprecher E, et al. Failure of initial disease control in bullous pemphigoid: a retrospective study of hospitalized patients in a single tertiary center. Int J Dermatol. 2017;56(10):1010–1016.
   PubMed Web of Science ®Google Scholar
• Paul MA, Jorizzo JL, Fleischer AB, Jr, et al. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1994;31(4):620–625.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–678.
   PubMed Web of Science ®Google Scholar
• Ramanan A-W,N, Ota S, Parker S, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52(11):3570–3578.
   PubMed Web of Science ®Google Scholar
• Click JW, Qureshi AA, Vleugels RA. Methotrexate for the treatment of cutaneous dermatomyositis. J Am Acad Dermatol. 2013;68(6):1043–1045.
   PubMed Web of Science ®Google Scholar
• Zieglschmid-Adams M, Pandya A, Cohen S, et al. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 1995;32(5 Pt 1):754–757.
   PubMed Web of Science ®Google Scholar
• Chen KS, Tan TH, Yesudian PD. Clinical, demographic and laboratory characteristics of methotrexate-responsive eczema. J Eur Acad Dermatol Venereol. 2016;30(11):e158–e159.
   PubMed Web of Science ®Google Scholar
• Shaffrali FC, Colver GB, Messenger AG, et al. Experience with low-dose methotrexate for the treatment of eczema in the elderly. J Am Acad Dermatol. 2003;48(3):417–419.
   PubMed Web of Science ®Google Scholar
• Berianu F, Cohen MD, Abril A, et al. Eosinophilic fasciitis: clinical characteristics and response to methotrexate. Int J Rheum Dis. 2015;18(1):91–98.
   PubMed Web of Science ®Google Scholar
• Lebeaux D, Frances C, Barete S, et al. Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology. 2012;51(3):557–561.
   PubMed Web of Science ®Google Scholar
• Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999;26(6):1275–1279.
   PubMed Web of Science ®Google Scholar
• Islam MN, Hossain M, Haq SA, et al. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis. 2012;15(1):62–68.
   PubMed Web of Science ®Google Scholar
• Arfi S, Numeric P, Grollier L, et al. [Treatment of corticodependent systemic lupus erythematosus with low-dose methotrexate]. Rev Med Intern. 1995;16(12):885–890.
   PubMed Web of Science ®Google Scholar
• Boehm I. Decrease of B-cells and autoantibodies after low-dose methotrexate. Biomed Pharmacother. 2003;57(7):278–281.
   PubMed Web of Science ®Google Scholar
• Fruchter R, Kurtzman DJB, Patel M, et al. Characteristics and alternative treatment outcomes of antimalarial-refractory cutaneous lupus erythematosus. JAMA Dermatol. 2017;153(9):937–939.
   PubMed Web of Science ®Google Scholar
• Kan H, Nagar S, Patel J, et al. Longitudinal treatment patterns and associated outcomes in patients with newly diagnosed systemic lupus erythematosus. Clin Ther. 2016;38(3):610–624.
   PubMed Web of Science ®Google Scholar
• Wenzel J, Brahler S, Bauer R, et al. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol. 2005;153(1):157–162.
   PubMed Web of Science ®Google Scholar
• Chauhan P, De D, Handa S, et al. A prospective observational study to compare efficacy of topical triamcinolone acetonide 0.1% oral paste, oral methotrexate, and a combination of topical triamcinolone acetonide 0.1% and oral methotrexate in moderate to severe oral lichen planus. Dermatol Ther. 2018;31(1):e12563.
   PubMed Web of Science ®Google Scholar
• Torti DC, Jorizzo JL, McCarty MA. Oral lichen planus: a case series with emphasis on therapy. Arch Dermatol. 2007;143(4):511–515.
   PubMedGoogle Scholar
• Turan H, Baskan EB, Tunali S, et al. Methotrexate for the treatment of generalized lichen planus. J Am Acad Dermatol. 2009;60(1):164–166.
   PubMed Web of Science ®Google Scholar
• Kortekangas-Savolainen O, Kiilholma P. Treatment of vulvovaginal erosive and stenosing lichen planus by surgical dilatation and methotrexate. Acta Obstet Gynecol Scand. 2007;86(3):339–343.
   PubMed Web of Science ®Google Scholar
• Babahosseini H, Tavakolpour S, Mahmoudi H, et al. Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients. J Dermatolog Treat. 2019;30(6):598–604.
   PubMed Web of Science ®Google Scholar
• Bulbul Baskan E, Yazici S. Treatment of lichen planopilaris: methotrexate or cyclosporine a therapy? Cutan Ocul Toxicol. 2018;37(2):196–194.
   PubMed Web of Science ®Google Scholar
• Kerkemeyer KLS, Green J. Lichen planopilaris: a retrospective study of 32 cases in an Australian tertiary referral hair clinic. Australas J Dermatol. 2018;59(4):297–301.
   PubMed Web of Science ®Google Scholar
• Bakhtiar R, Noor SM, Paracha MM. Effectiveness of oral methotrexate therapy versus systemic corticosteroid therapy in treatment of generalised lichen planus. J Coll Physicians Surg Pak. 2018;28(7):505–508.
   PubMed Web of Science ®Google Scholar
• Naeini FF, Saber M, Asilian A, et al. Clinical efficacy and safety of methotrexate versus hydroxychloroquine in preventing lichen planopilaris progress: a randomized clinical trial. Int J Prev Med. 2017;8(37):37.
   PubMedGoogle Scholar
• Bulur I, Erdoğan HK, Karapınar T, et al. Morphea in Middle Anatolia, Turkey: a 5-year single-center experience. Postepy Dermatol Alergol. 2017;34(4):334–338.
   PubMed Web of Science ®Google Scholar
• Li SC, Torok KS, Rabinovich CE, et al. Initial results from a pilot comparative effectiveness study of three methotrexate-based consensus treatment plans for juvenile localized scleroderma. J Rheumatol. 2020;47:1242–1252.
   PubMed Web of Science ®Google Scholar
• Mirsky L, Chakkittakandiyil A, Laxer RM, et al. Relapse after systemic treatment in paediatric morphoea. Br J Dermatol. 2012;166(2):443–445.
   PubMed Web of Science ®Google Scholar
• Piram M, McCuaig CC, Saint-Cyr C, et al. Short- and long-term outcome of linear morphoea in children. Br J Dermatol. 2013;169(6):1265–1271.
   PubMed Web of Science ®Google Scholar
• Uziel Y, Feldman BM, Krafchik BR, et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr. 2000;136(1):91–95.
   PubMed Web of Science ®Google Scholar
• Weibel L, Sampaio MC, Visentin MT, et al. Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children. Br J Dermatol. 2006;155(5):1013–1020.
   PubMed Web of Science ®Google Scholar
• Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol. 2005;141(7):847–852.
   PubMedGoogle Scholar
• Seyger MM, van den Hoogen FH, de Boo T, et al. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol. 1998;39(2):220–225.
   PubMed Web of Science ®Google Scholar
• Wlodek C, Korendowych E, McHugh N, et al. Morphoea profunda and its relationship to eosinophilic fasciitis. Clin Exp Dermatol. 2018;43(3):306–310.
   PubMed Web of Science ®Google Scholar
• Allison DS, El-Azhary RA, Calobrisi SD, et al. Pityriasis rubra pilaris in children. J Am Acad Dermatol. 2002;47(3):386–389.
   PubMed Web of Science ®Google Scholar
• Chapalain V, Beylot-Barry M, Doutre MS, et al. Treatment of pityriasis rubra pilaris: a retrospective study of 14 patients. J Dermatolog Treat. 1999;10(2):113–117.
   Web of Science ®Google Scholar
• Dicken CH. Treatment of classic pityriasis rubra pilaris. J Am Acad Dermatol. 1994;31(6):997–999.
   PubMed Web of Science ®Google Scholar
• Knowles WR, Chernosky ME. Pityriasis rubra pilaris. Prolonged treatment with methotrexate. Arch Dermatol. 1970;102(6):603–612.
   PubMedGoogle Scholar
• Lever WF. Methotrexate and prednisone in pemphigus vulgaris. Therapeutic results obtained in 36 patients between 1961 and 1970. Arch Dermatol. 1972;106(4):491–497.
   PubMedGoogle Scholar
• Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris. A 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol. 1988;68(5):413–421.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol. 1999;135(10):1275–1276.
   PubMedGoogle Scholar
• Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995;155(8):846–851.
   PubMedGoogle Scholar
• Veien NK, Brodthagen H. Cutaneous sarcoidosis treated with methotrexate. Br J Dermatol. 1977;97(2):213–216.
   PubMed Web of Science ®Google Scholar
• Herrick AL, Pan X, Peytrignet S, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017;76(7):1207–1218.
   PubMed Web of Science ®Google Scholar
• Sumanth M, Sharma VK, Khaitan BK, et al. Evaluation of oral methotrexate in the treatment of systemic sclerosis. Int J Dermatol. 2007;46(2):218–223.
   PubMed Web of Science ®Google Scholar
• van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35(4):364–372.
   PubMedGoogle Scholar
• Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44(6):1351–1358.
   PubMed Web of Science ®Google Scholar
• Leducq S, Samimi M, Bernier C, et al. Efficacy and safety of methotrexate add-on therapy versus placebo for patients with chronic spontaneous urticaria resistant to H1-antihistamines: a randomized, controlled trial. J Am Acad Dermatol. 2020;82:240–243.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Singh S, Ramam M, et al. A randomized placebo-controlled double-blind pilot study of methotrexate in the treatment of H1 antihistamine-resistant chronic spontaneous urticaria. Indian J Dermatol Venereol Leprol. 2014;80(2):122–128.
   PubMed Web of Science ®Google Scholar
• Kalyoncu U, Solmaz D, Emmungil H, et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset still's disease: data from a large multicenter cohort. J Autoimmun. 2016;69:59–63.
   PubMed Web of Science ®Google Scholar
• Patel A, Burns E, Burkemper NM. Methotrexate use in allergic contact dermatitis: a retrospective study. Contact Dermatitis. 2018;78(3):194–198.
   PubMed Web of Science ®Google Scholar
• Hossain D. Using methotrexate to treat patients with ENL unresponsive to steroids and clofazimine: a report on 9 patients. Lepr Rev. 2013;84(1):105–112.
   PubMed Web of Science ®Google Scholar
• Politiek K, van der Schaft J, Christoffers WA, et al. Drug survival of methotrexate treatment in hand eczema patients: results from a retrospective daily practice study. J Eur Acad Dermatol Venereol. 2016;30(8):1405–1407.
   PubMed Web of Science ®Google Scholar
• Fernandez-de-Misa R, Hernandez-Machin B, Servitje O, et al. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. Clin Exp Dermatol. 2018;43(2):137–143.
   PubMed Web of Science ®Google Scholar
• Torrelo A, Noguera-Morel L, Hernandez-Martin A, et al. Recurrent lipoatrophic panniculitis of children. J Eur Acad Dermatol Venereol. 2017;31(3):536–543.
   PubMed Web of Science ®Google Scholar
• Moustafa FA, Sandoval LF, Jorizzo JL, et al. Systemic treatment of papular dermatitis: a retrospective study. J Dermatolog Treat. 2015;26(5):431–434.
   PubMed Web of Science ®Google Scholar
• Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. Clin Exp Dermatol. 2014;39(4):468–473.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Bhat R, Sethuraman G, et al. Treatment of parthenium dermatitis with methotrexate. Contact Dermatitis. 2007;57(2):118–119.
   PubMed Web of Science ®Google Scholar
• Klejtman T, Beylot-Barry M, Joly P, et al. Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. J Eur Acad Dermatol Venereol. 2018;32(3):437–440.
   PubMed Web of Science ®Google Scholar
• Karadag AS, Akdeniz N, Ozlu E, et al. Effect of pulse corticosteroids and low dose methotrexate in cases of treatment-resistant lichen sclerosus. Dermatol Sinica. 2018;36(4):248–249.
   Web of Science ®Google Scholar
• Kreuter A, Tigges C, Gaifullina R, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate treatment in patients with refractory generalized extragenital lichen sclerosus. Arch Dermatol. 2009;145(11):1303–1308.
   PubMedGoogle Scholar
• Nast A, Smith CD, Spuls PI, et al. EuroGuiderm guideline for the systemic treatment of psoriasis vulgaris; 2020 [cited 2020 Dec 13]. Available from: https://www.edf.one/dam/jcr:c80dd166-c66f-4548-a7ed-754f5e2687d0/Living_Euroguiderm_guideline_psoriasis_vulgaris.pdf
   Google Scholar
• Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E initiative. Ann Rheum Dis. 2009;68(7):1086–1093.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1(1):Cd011535.
   PubMedGoogle Scholar
• Wilkes M, Johns M. Informed consent and shared decision-making: a requirement to disclose to patients off-label prescriptions. PLOS Med. 2008;5(11):e223.
   PubMed Web of Science ®Google Scholar
• Elwyn G, Laitner S, Coulter A, et al. Implementing shared decision making in the NHS. Br Med J. 2010;341:c5146.
   PubMed Web of Science ®Google Scholar
• Spuls PI, Gerbens LAA, Apfelbacher CJ, et al. The international TREatment of ATopic eczema (TREAT) registry taskforce: an initiative to harmonize data collection across national atopic eczema photo- and systemic therapy registries. J Invest Dermatol. 2017;137(9):2014–2016.
   PubMed Web of Science ®Google Scholar